Dean Y. Li
Executive VP & President of Merck Research LaboratoriesDr. Dean Y. Li, M.D. Ph.D, is Executive VP of Merck Sharp & Dohme LLC and has been its President of MSD Research Laboratories since January 2021. He Co-Founded Recursion Pharmaceuticals, Inc in November 2013 and also serves as Director 2026 and served as Independent Director of Recursion Pharmaceuticals, Inc since November 2013 until November 2025 and served as its Chief Scientific Officer. Dr. Li has been Executive Vice President and President of Merck Research Laboratories at Merck & Co., Inc. since January 2021. Dr. Li previously served as Senior Vice President of Discovery Sciences and Translational Medicine, Merck Research Laboratories from November 2017 to January 2021. Dr. Li serves as an Associate Professor of Medicine in the departments of Oncological Sciences and Medicine at the University of Utah. Dr. Li served as the Interim Chief Executive Officer at ARUP Laboratories, Inc. until August 16, 2016. He is a leading researcher in defining mechanisms of vascular development and disease, including the effects of inadequate or undesirable vascular regeneration and the development of novel therapies for vascular disease. Dr. Li serves as a Scientific Co-Founder and Member of Scientific Advisory Board for Hydra Biosciences, Inc. Dr. Li served as the H.A. & Edna Benning Professor of Medicine and Cardiology, the vice-dean of research at the University of Utah Health Science Center and as the chief scientific officer of University of Utah Health Care. Dr. Li served as Vice President, Translational Medicine (March 2017-November 2017) at Merck & Co. Inc. Dr. Li served as a Member of Scientific Advisory Board of Ion Channel and Cardiac Regeneration for Hydra Biosciences, Inc. He is a Culpeper Medical Science Scholar, American Cancer Society Research Scholar and Director of the Vascular Biotherapeutics Center at the University of Utah, a Center of Excellence funded by the Utah Office of Technology Development. He is a member of the Eccles Program of Human Molecular Biology and Genetics. Dr. Li also served as interim chief executive officer of Associated Regional University Pathologists, the nation’s third-largest clinical reference laboratory, from June 2015 to August 2016. Dr. Li trained at Washington University in Saint Louis before moving to the University of Utah to work as a post-doctoral scientist in the laboratory of Mark Keating. Dr. Li earned M.D. and Ph.D. in Molecular Cell Biology at Washington University and B.S. in Chemistry from the University of Chicago.
Positions
- Company NameMerck & Co., Inc.Stock CodeMRKPositionExecutive VP & President of Merck Research LaboratoriesColleagues
- RMRobert M. DavisChairman, President & CEO
- CACaroline A. LitchfieldExecutive VP & CFO
- JLJennifer L. ZacharyExecutive VP & General Counsel
- DEDalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller
- THThomas Henry GlocerIndependent Lead Director
- PFPatricia F. RussoIndependent Director
- PJPamela J. CraigIndependent Director
- PBPaul B. RothmanIndependent Director
